Cholangiocarcinoma

The AJMC® Cholangiocarcinoma compendium is a comprehensive resource for clinical news and expert insights about this rare cancer of the bile duct.

Latest News
December 19th 2022

Postoperative TACE Prolongs RFS in Patients With Combined Hepatocellular-Cholangiocarcinoma

December 15th 2022

Case Report Details Diagnostic Imaging for Rare Distal Cholangiocarcinoma Case

November 30th 2022

Surveillance Program Ineffective at Detecting Cholangiocarcinoma Early Enough for Benefit in Patients With PSC

November 29th 2022

Study: FGFR mRNA Overexpression Occurs Frequently for Those With Cholangiocarcinoma

November 25th 2022

FGFR Inhibitors Show Promise in Cholangiocarcinoma but Face Acquired Resistance

Video Interviews
View All
March 18th 2022

Dr Sunil Verma on Advancements in Cholangiocarcinoma Standards of Care

March 4th 2022

Dr Sunil Verma Discusses Safety Findings of TOPAZ-1 Trial

February 25th 2022

Dr Sunil Verma Discusses Adding Durvalumab to Cholangiocarcioma Chemotherapy Combination

February 7th 2022

Dr Sunil Verma on Background, Results of TOPAZ-1 Study

Podcasts
View All
May 24th 2022

Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer

More News

cance cell and DNA strand
November 24th 2022

Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

Jonah Feldman
A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement.
Physician monitoring a patient
October 28th 2022

Risk of HCC Warrants Careful Surveillance in People With Primary Biliary Cholangitis

Jared Kaltwasser
It is unclear what role treatment plays in affecting hepatocellular carcinoma (HCC) risk, the authors found.
graphic depicting liver medicine
October 24th 2022

Swedish Study Finds Increasing Prevalence of Biliary Tract Cancers Among Younger Adults

Jared Kaltwasser
Intrahepatic and perihilar cholangiocarcinoma, in particular, grew faster in young patients than in older patients.
picture of hospital hallway
October 18th 2022

Robotic Surgery Offers Potential New Strategy for Hilar Cholangiocarcinoma Resection

Jared Kaltwasser
A new report consolidates existing research on hilar cholangiocarcinoma resection, but finds more work is needed to better evaluate the efficacy of robotic surgery in these patients.
image of survival
October 14th 2022

C-Reactive Protein Could Predict Survival in Patients With ICC Taking PD-1 Inhibitors

Jared Kaltwasser
A new report finds inflammation scores can predict outcomes among patients receiving immunotherapy for intrahepatic cholangiocarcinoma (ICC).
graphic of liver
October 12th 2022

Identifying Comorbidities That Heighten Risk for Particular Hepatobiliary Cancers

Jared Kaltwasser
Risk for individual hepatobiliary cancers varies from comorbidity to comorbidity, researchers found.
Image of medical data
October 6th 2022

Primary Sclerosing Cholangitis Treatment Varies Significantly Among Care Centers

Jared Kaltwasser
The survey of European hepatologists demonstrates the lack of clarity in guidelines.
Image of surgeons discussing their findings
September 29th 2022

Four Predictors of Early Recurrence After PHCC Resection Found in New Study

Jared Kaltwasser
Patients in the highest risk category had a 65% chance of recurrence of their perihilar cholangiocarcinoma (PHCC) within 1 year, this new study has found.
Image of liver surgery
September 26th 2022

Composite Quality Metric Can Help Predict Surgical Outcomes in ICC

Jared Kaltwasser
Only about 11% of patients received care meeting a composite quality metric, a study found.
graphic of genomic code
September 24th 2022

Study Supports Comprehensive Genomic Profiling for Patients With Biliary Tract Cancer

Rose McNulty
A small study suggests that comprehensive genomic profiling can help with clinical decision-making and predicting clinical outcomes in advanced biliary tract cancer, but further research is needed.
image of liver
September 24th 2022

Case Report Describes Youngest Recorded Patient With Intrahepatic Sarcomatoid Cholangiocarcinoma

Rose McNulty
The rare condition can easily be confused with hepatocellular carcinoma, but immunohistochemical studies can help accurately diagnose intrahepatic sarcomatoid cholangiocarcinoma.
image of a sick patient
September 12th 2022

Many Patients With iCCA Still Do Not Get Curative Treatment

Jared Kaltwasser
About 4 in 10 patients do not receive curative therapy despite early detection, a new study shows.
DNA mutation
September 7th 2022

Understanding Mechanisms, Strategies for Secondary IDH1-Inhibitor Resistance in IHCC

Jared Kaltwasser
The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC).
Durvalumab With Chemo Wins FDA Approval in Treatment of Biliary Tract Cancers
September 6th 2022

Durvalumab With Chemo Wins FDA Approval in Treatment of Biliary Tract Cancers

Mary Caffrey
An estimated 1 in 4 patients treated with durvalumab and chemotherapy (gemcitabine plus cisplatin) was alive at 2 years compared with 1 in 10 treated with chemotherapy alone, with these results contributing to the FDA's approval of the first immunotherapy to treat these cancers.
picture of New Orleans
September 6th 2022

Incidence, Outcomes of HCC in Louisiana Continue to Lag Behind Nation

Jared Kaltwasser
The increase in the incidence of hepatocellular carcinoma in Louisiana was nearly double that of the United States as a whole between 2005 and 2015.
Nestin May Help Diagnose, Risk-Stratify Patients With Rare Form of CCA
August 28th 2022

Nestin May Help Diagnose, Risk-Stratify Patients With Rare Form of CCA

Jared Kaltwasser
New research suggests Nestin expression can help distinguish combined hepatocellular-cholangiocarcinomas (CCAs) from hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Image of surgery
August 22nd 2022

Biliary Drainage Often Unsuccessful in Perihilar Cholangiocarcinoma

Jared Kaltwasser
The procedure can be beneficial prior to chemotherapy, but it also has high rates of complications, this new analysis shows.
Image of DNA
August 17th 2022

Biomarker Testing Increasingly Important, But Still Challenging, in iCCA

Jared Kaltwasser
A new report offers insights from a multidisciplinary team of experts on intrahepatic cholangiocarcinoma (iCCA).
picture of surgery
August 15th 2022

Rare Surgical Procedure a Viable Option for Some Patients With Locally Advanced CCA

Jared Kaltwasser
A case report shows the potential of hepatopancreatoduodenectomy for certain patients who might otherwise be thought to have unresectable tumors
Image of immunotherapy
August 11th 2022

Anti–PD-1 Therapy Likely Leads to Responses in Advanced ICC

Jared Kaltwasser
The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%.
Image of bile ducts
August 4th 2022

Atezolizumab/Bevacizumab Shown Effective Against CHC

Jared Kaltwasser
The combination is approved to treat hepatocellular carcinoma (HCC), but this case report suggests it can also work for combined HCC and cholangiocarcinoma (CHC).
Image of clinical research
August 1st 2022

LI-RADS Classification May Help Risk-Stratify Patients With iCCA

Jared Kaltwasser
Investigators say classification based on magnetic resonance imaging can predict a patient’s risk of recurrence for intrahepatic cholangiocarcinoma (iCCA).
Image of a stethoscope on hundred dollar bills
July 27th 2022

Trials, Targeted Agents Often Lead to Financial Toxicity From CCA

Jared Kaltwasser
Clinical trials and targeted agents do not appear to affect health care–related quality of life, however.
Image of a sick patient
July 21st 2022

CCA Prognosis Remains Poor as Prevalence, Potential Treatments Grow

Jared Kaltwasser
A new review article notes efforts to diagnose cholangiocarcinoma (CCA) early are hampered by a lack of biomarkers.
Image of research
July 15th 2022

Nomogram Could Help Predict Early Recurrence Risk in ICC

Jared Kaltwasser
The tool could help clinicians better screen patients for adjuvant chemotherapy following curative resection for intrahepatic cholangiocarcinoma (ICC).
Image of a surgical room
July 15th 2022

ICC Rates on the Rise Among Certain Patient Groups

Jared Kaltwasser
Data show surgery leads to the best outcomes.
picture of molecules
July 9th 2022

Review Highlights Potential Targets for Precision Medicine in Cholangiocarcinoma

Rose McNulty
The prognosis for cholangiocarcinoma remains poor despite advances in targeted therapy, but several targets hold promise for improving treatment strategies and patient outcomes.
Researchers From Spain Find Option to Detect FGFR2 Fusion in Plasma
July 2nd 2022

Researchers From Spain Find Option to Detect FGFR2 Fusion in Plasma

Mary Caffrey
Vall d'Hebron Institute of Oncology, a research group from Barcelona, Spain, has presented a method to detect FGFR2 fusion in plasma, which they say is “especially relevant” since the arrival of pemigatinib to treat patients with recurrent intrahepatic cholangiocarcinoma (iCCA).
Image of genetic research
June 24th 2022

MSI-High Status Linked With PD-1 Therapy Response in Cholangiocarcinoma

Jared Kaltwasser
Just 5% of patients in a cholangiocarcinoma cohort were categorized as microsatellite instability high (MSI-high), but those patients tended to have “excellent” responses to therapy.
Image of a medical center
June 18th 2022

Progress Made in Classifying iCCA, but Challenges Remain, Review Says

Jared Kaltwasser
A dichotomous classification scheme has helped in the intrahepatic cholangiocarcinoma (iCCA) space, but some potential variants require further exploration, the article states.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo